The University of Texas MD Anderson Cancer Center CIMAC is comprised of a multi-disciplinary group of highly collaborative experts, all of whom have large-scale institutional and national biorepository experience. This includes experience in longitudinal collection and “real-time” immune- profiling analysis of samples in immunotherapy trials. Furthermore, the group also has previously participated in integral, integrated and correlative biomarker analysis with NCI-Sponsored Network Groups (NCTN). This includes the Eastern Cooperative Oncology Group – American College of Radiology Imaging Network (ECOG-ACRIN) and the Southwest Oncology Group (SWOG). MDACC also provides access to a great deal of computational and statistical resources, such as centralized data banking, advanced statistical pipelines for multi-platform high-throughput “omics” data integration and the Translational Research Accelerator(TRA)/Big Data Platform.
Ignacio Wistuba, MD
Ignacio Wistuba, MD, is a professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. He is also Department Chair of the Department of Translational Molecular Pathology at the institution as well. Dr. Wistuba’s research facility utilizes advanced molecular biology and pathology equipment for comprehensive molecular profiling of lung cancer samples.
Chantale Bernatchez, PhD
Chantale Bernatchez, PhD is an assistant professor in the department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. Her main research interest is in the immunotherapy of cancer with a specialized focus on T cell therapy utilizing tumor infiltrating lymphocytes(TILs). She specializes in using molecular and immunological assays to define biomarkers that could predict responses to TIL therapy.
Gheath Al-Atrash, MD PhD
Gheath Al-Atrash, MD PhD, is an associate professor in the department of Stem Cell Transplantation at the University of Texas MD Anderson Cancer Center. He is a physician-scientist who focused on developing novel immunotherapies primarily for hematologic malignancies as well as some solid tumors. Dr. Al-Atrash also studies antigen presentation/ cross-presentation mechanisms in solid tumors and the value of immune checkpoint blockade in leukemia.